These things happen
This past Friday two events spooked the diabetes device world. The first was news that Abbott filed an IP lawsuit against Dexcom, the second Insulet announced the OmniPod 5 approval would not come before the end of 2021 more likely sometime in the first quarter of 2022. Shares of Dexcom fell over 7% on the news while shares of Insulet fell over 8%. Over the past month shares of Dexcom have fallen slightly over 16% while shares of Insulet have fallen almost 16%.
Let’s make it clear from the start that neither event will have a long-term . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.